tirzepatide cvot results Cardiovascular outcomes of semaglutide and for patients with type 2 diabetes in clinical practice Can Dual Incretin Receptor Agonists

If you see floaters, flakes, or any solid particles in the vial or pen, the medication has likely broken down or precipitated. This makes the medication unsafe for injection

Researchers theorize this may be because: GIP activation may counterbalance some GLP-1 effects on the gut Dose escalation schedule allows more gradual adaptation Different pharmacokinetic profile may produce less pronounced peaks Serious Side Effects (Both Medications): These are rare but require immediate medical attention: Pancreatitis: Severe abdominal pain that may radiate to the back Risk: Less than 1% with both medications Usually occurs in first few months of treatment Requires immediate discontinuation if suspected Gallbladder Problems: Gallstones, cholecystitis (gallbladder inflammation) Symptoms: Right upper abdominal pain, nausea, fever More common with rapid weight loss May require surgical intervention Kidney Problems: Dehydration from vomiting/diarrhea can affect kidney function Watch for decreased urination, swelling in legs Stay well-hydrated, especially during side effect periods Thyroid Tumors (Black Box Warning): Both medications carry warnings about thyroid C-cell tumors Based on rodent studies

Each is a decision made in conversation with a licensed provider, not a self-titration

Tirzepatide may be considered for patients who may benefit from dual GIP and GLP-1 activity

if you weigh less or have lower muscle mass goals, aim toward the lower range